市場調査レポート

商品コード

1193051

白血球除去療法市場：製品別、メソッド別、用途別、エンドユーザー別：世界の機会分析および産業予測、2021-2031年

Leukapheresis Market By Product, By Method, By Application, By End User : Global Opportunity Analysis and Industry Forecast, 2021-2031

出版日: 2022年10月01日 | 発行: Allied Market Research

| ページ情報: 英文 274 Pages | 納期: 2～3営業日

価格

PDF (Single User License)

USD 5,730 898,234円

レポートPDFを1つのPCでご利用頂けるライセンスです。ライセンスを付与されたPCでのみレポートPDFの保存、表示、利用が可能です。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は1回だけ可能です。印刷したレポートの利用もPDFのライセンス保持者になります。回覧のための複製も原則NGです。

PDF (5-user License)

USD 6,450 1,011,102円

レポートPDFを5名でご利用頂けるライセンスです。ライセンスを付与されたPCでのみレポートPDFの保存、表示、利用が可能です。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は5回可能です。印刷したレポートの利用もPDFのライセンス保持者5名となります。

PDF (Enterprise User License) & Excel (Data Pack) & Free Update

USD 9,600 1,504,896円

レポートPDFとExcel定量データをひとつの企業、及びその子会社でご利用頂けるライセンスです。ライセンスを付与されたPCでのみレポートPDFとExcelの保存、表示、利用が可能です。PDFとExcel内のテキスト等のコピー＆ペーストは可能です。PDFとExcelの印刷回数の制限はありません。印刷したレポートの利用は企業、及びその子会社内にて共有可能です。無料でレポートのアップデートがご利用いただけます。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=156.76円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

世界の白血球除去療法市場は、2021年に2億4565万米ドルで、2031年には5億6164万米ドルに達すると予測され、2022年から2031年までのCAGRは8.6%と登録されています。

白血球除去療法とは、血液サンプルから白血球を除去する実験室での処置のことです。このプロセスでは、血液は白血球を取り出し、他のすべての血球と血漿を血流に戻す機械を通過します。さらに、このプロセスでは、2本の静脈（IV）ラインを体内に挿入します。1本の点滴ラインは血液を除去し、もう1本はきれいになった血液を体内に戻します。この処置には約2～3時間かかります。

白血病の発生率と有病率の増加により、白血球除去療法の需要が増加することが、世界の白血球除去療法市場の成長の主な要因となっています。また、献血の需要の増加や、臨床研究調査における白血球除去療法の需要の増加が市場成長を担っています。さらに、米国などの新興国における白血球生成手順に関する認知度の向上が、市場の成長をさらに後押ししています。しかし、新興諸国では白血球除去治療薬や白血球除去療法、輸血の安全性に関連するコストが高く、市場成長の妨げとなっています。逆に、小児患者における白血球除去療法の需要の増加は、市場参加者に有利な機会を提供すると予想されます。

概要
- 市場規模および予測
遠心分離法
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場分析：国別分析
メンブレンセパレーション
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場分析：国別
選択的吸着
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場分析：国別

第6章白血球除去療法市場：用途別

概要
- 市場規模・予測
治療用用途
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場分析：国別分析
調査用途
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場分析：国別

第7章白血球除去療法市場：エンドユーザー別

概要
- 市場規模・予測
血液センター
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場分析：国別
病院
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場分析：国別
その他
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場分析：国別

第8章白血球除去療法市場：地域別

概要
- 市場規模・予測
北米
- 主要動向と機会
- 北米市場規模・予測：製品別
- 北米市場規模・予測：方式別
- 北米市場規模・予測：用途別
- 北米市場規模・予測：エンドユーザー別
- 北米市場規模・予測：国別
  - 米国
  - カナダ
  - メキシコ
欧州
- 主な動向と機会
- 欧州の市場規模・予測：製品別
- 欧州市場規模・予測：メソッド別
- 欧州市場規模・予測：用途別
- 欧州市場規模・予測：エンドユーザー別
- 欧州市場規模・予測：国別
  - ドイツ
  - フランス
  - 英国
  - イタリア
  - スペイン
  - その他欧州
アジア太平洋地域
- 主な動向と機会
- アジア太平洋地域の市場規模・予測：製品別
- アジア太平洋地域の市場規模・予測：メソッド別
- アジア太平洋地域の市場規模・予測：用途別
- アジア太平洋地域の市場規模・予測：エンドユーザー別
- アジア太平洋地域の市場規模・予測：国別
  - 日本
  - 中国
  - インド
  - オーストラリア
  - 韓国
  - その他アジア太平洋地域
LAMEA
- 主な動向と機会
- LAMEAの市場規模・予測：製品別
- LAMEAの市場規模・予測：方式別
- LAMEAの市場規模・予測：用途別
- LAMEAの市場規模・予測：エンドユーザー別
- LAMEAの市場規模・予測：国別
  - ブラジル
  - サウジアラビア
  - 南アフリカ共和国
  - LAMEAの残りの地域

第9章企業情勢

イントロダクション
主要成功戦略
主要10社の製品マッピング
競合ダッシュボード
競合のヒートマップ
主な発展

第10章企業プロファイル

Adacyte Therapeutics
AllCells, LLC.
Asahi Kasei Corporation
Charles River Laboratories International, Inc.
Cerus Corporation
Fresenius Kabi
Haemonetics Corporation
Macopharma
SB-Kawasumi Laboratories, Inc.
Terumo BCT, Inc.

図表

LIST OF TABLES

TABLE 1. GLOBAL LEUKAPHERESIS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 2. LEUKAPHERESIS MARKET, FOR DEVICES, BY REGION, 2021-2031 ($MILLION)
TABLE 3. LEUKAPHERESIS MARKET FOR DEVICES, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 4. LEUKAPHERESIS MARKET, FOR DISPOSABLES, BY REGION, 2021-2031 ($MILLION)
TABLE 5. LEUKAPHERESIS MARKET FOR DISPOSABLES, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 6. GLOBAL LEUKAPHERESIS MARKET, BY METHOD, 2021-2031 ($MILLION)
TABLE 7. LEUKAPHERESIS MARKET, FOR CENTRIFUGATION, BY REGION, 2021-2031 ($MILLION)
TABLE 8. LEUKAPHERESIS MARKET FOR CENTRIFUGATION, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 9. LEUKAPHERESIS MARKET, FOR MEMBRANE SEPARATION, BY REGION, 2021-2031 ($MILLION)
TABLE 10. LEUKAPHERESIS MARKET FOR MEMBRANE SEPARATION, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 11. LEUKAPHERESIS MARKET, FOR SELECTIVE ADSORPTION, BY REGION, 2021-2031 ($MILLION)
TABLE 12. LEUKAPHERESIS MARKET FOR SELECTIVE ADSORPTION, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 13. GLOBAL LEUKAPHERESIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 14. LEUKAPHERESIS MARKET, FOR THERAPEUTIC APPLICATIONS, BY REGION, 2021-2031 ($MILLION)
TABLE 15. LEUKAPHERESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 16. LEUKAPHERESIS MARKET, FOR RESEARCH APPLICATIONS, BY REGION, 2021-2031 ($MILLION)
TABLE 17. LEUKAPHERESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 18. GLOBAL LEUKAPHERESIS MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 19. LEUKAPHERESIS MARKET, FOR BLOOD CENTERS, BY REGION, 2021-2031 ($MILLION)
TABLE 20. LEUKAPHERESIS MARKET FOR BLOOD CENTERS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 21. LEUKAPHERESIS MARKET, FOR HOSPITALS, BY REGION, 2021-2031 ($MILLION)
TABLE 22. LEUKAPHERESIS MARKET FOR HOSPITALS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 23. LEUKAPHERESIS MARKET, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
TABLE 24. LEUKAPHERESIS MARKET FOR OTHERS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 25. LEUKAPHERESIS MARKET, BY REGION, 2021-2031 ($MILLION)
TABLE 26. NORTH AMERICA LEUKAPHERESIS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 27. NORTH AMERICA LEUKAPHERESIS MARKET, BY METHOD, 2021-2031 ($MILLION)
TABLE 28. NORTH AMERICA LEUKAPHERESIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 29. NORTH AMERICA LEUKAPHERESIS MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 30. NORTH AMERICA LEUKAPHERESIS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 31. U.S. LEUKAPHERESIS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 32. U.S. LEUKAPHERESIS MARKET, BY METHOD, 2021-2031 ($MILLION)
TABLE 33. U.S. LEUKAPHERESIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 34. U.S. LEUKAPHERESIS MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 35. CANADA LEUKAPHERESIS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 36. CANADA LEUKAPHERESIS MARKET, BY METHOD, 2021-2031 ($MILLION)
TABLE 37. CANADA LEUKAPHERESIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 38. CANADA LEUKAPHERESIS MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 39. MEXICO LEUKAPHERESIS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 40. MEXICO LEUKAPHERESIS MARKET, BY METHOD, 2021-2031 ($MILLION)
TABLE 41. MEXICO LEUKAPHERESIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 42. MEXICO LEUKAPHERESIS MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 43. EUROPE LEUKAPHERESIS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 44. EUROPE LEUKAPHERESIS MARKET, BY METHOD, 2021-2031 ($MILLION)
TABLE 45. EUROPE LEUKAPHERESIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 46. EUROPE LEUKAPHERESIS MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 47. EUROPE LEUKAPHERESIS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 48. GERMANY LEUKAPHERESIS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 49. GERMANY LEUKAPHERESIS MARKET, BY METHOD, 2021-2031 ($MILLION)
TABLE 50. GERMANY LEUKAPHERESIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 51. GERMANY LEUKAPHERESIS MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 52. FRANCE LEUKAPHERESIS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 53. FRANCE LEUKAPHERESIS MARKET, BY METHOD, 2021-2031 ($MILLION)
TABLE 54. FRANCE LEUKAPHERESIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 55. FRANCE LEUKAPHERESIS MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 56. UK LEUKAPHERESIS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 57. UK LEUKAPHERESIS MARKET, BY METHOD, 2021-2031 ($MILLION)
TABLE 58. UK LEUKAPHERESIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 59. UK LEUKAPHERESIS MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 60. ITALY LEUKAPHERESIS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 61. ITALY LEUKAPHERESIS MARKET, BY METHOD, 2021-2031 ($MILLION)
TABLE 62. ITALY LEUKAPHERESIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 63. ITALY LEUKAPHERESIS MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 64. SPAIN LEUKAPHERESIS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 65. SPAIN LEUKAPHERESIS MARKET, BY METHOD, 2021-2031 ($MILLION)
TABLE 66. SPAIN LEUKAPHERESIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 67. SPAIN LEUKAPHERESIS MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 68. REST OF EUROPE LEUKAPHERESIS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 69. REST OF EUROPE LEUKAPHERESIS MARKET, BY METHOD, 2021-2031 ($MILLION)
TABLE 70. REST OF EUROPE LEUKAPHERESIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 71. REST OF EUROPE LEUKAPHERESIS MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 72. ASIA-PACIFIC LEUKAPHERESIS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 73. ASIA-PACIFIC LEUKAPHERESIS MARKET, BY METHOD, 2021-2031 ($MILLION)
TABLE 74. ASIA-PACIFIC LEUKAPHERESIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 75. ASIA-PACIFIC LEUKAPHERESIS MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 76. ASIA-PACIFIC LEUKAPHERESIS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 77. JAPAN LEUKAPHERESIS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 78. JAPAN LEUKAPHERESIS MARKET, BY METHOD, 2021-2031 ($MILLION)
TABLE 79. JAPAN LEUKAPHERESIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 80. JAPAN LEUKAPHERESIS MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 81. CHINA LEUKAPHERESIS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 82. CHINA LEUKAPHERESIS MARKET, BY METHOD, 2021-2031 ($MILLION)
TABLE 83. CHINA LEUKAPHERESIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 84. CHINA LEUKAPHERESIS MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 85. INDIA LEUKAPHERESIS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 86. INDIA LEUKAPHERESIS MARKET, BY METHOD, 2021-2031 ($MILLION)
TABLE 87. INDIA LEUKAPHERESIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 88. INDIA LEUKAPHERESIS MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 89. AUSTRALIA LEUKAPHERESIS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 90. AUSTRALIA LEUKAPHERESIS MARKET, BY METHOD, 2021-2031 ($MILLION)
TABLE 91. AUSTRALIA LEUKAPHERESIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 92. AUSTRALIA LEUKAPHERESIS MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 93. SOUTH KOREA LEUKAPHERESIS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 94. SOUTH KOREA LEUKAPHERESIS MARKET, BY METHOD, 2021-2031 ($MILLION)
TABLE 95. SOUTH KOREA LEUKAPHERESIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 96. SOUTH KOREA LEUKAPHERESIS MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 97. REST OF ASIA-PACIFIC LEUKAPHERESIS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 98. REST OF ASIA-PACIFIC LEUKAPHERESIS MARKET, BY METHOD, 2021-2031 ($MILLION)
TABLE 99. REST OF ASIA-PACIFIC LEUKAPHERESIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 100. REST OF ASIA-PACIFIC LEUKAPHERESIS MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 101. LAMEA LEUKAPHERESIS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 102. LAMEA LEUKAPHERESIS MARKET, BY METHOD, 2021-2031 ($MILLION)
TABLE 103. LAMEA LEUKAPHERESIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 104. LAMEA LEUKAPHERESIS MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 105. LAMEA LEUKAPHERESIS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 106. BRAZIL LEUKAPHERESIS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 107. BRAZIL LEUKAPHERESIS MARKET, BY METHOD, 2021-2031 ($MILLION)
TABLE 108. BRAZIL LEUKAPHERESIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 109. BRAZIL LEUKAPHERESIS MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 110. SAUDI ARABIA LEUKAPHERESIS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 111. SAUDI ARABIA LEUKAPHERESIS MARKET, BY METHOD, 2021-2031 ($MILLION)
TABLE 112. SAUDI ARABIA LEUKAPHERESIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 113. SAUDI ARABIA LEUKAPHERESIS MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 114. SOUTH AFRICA LEUKAPHERESIS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 115. SOUTH AFRICA LEUKAPHERESIS MARKET, BY METHOD, 2021-2031 ($MILLION)
TABLE 116. SOUTH AFRICA LEUKAPHERESIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 117. SOUTH AFRICA LEUKAPHERESIS MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 118. REST OF LAMEA LEUKAPHERESIS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
TABLE 119. REST OF LAMEA LEUKAPHERESIS MARKET, BY METHOD, 2021-2031 ($MILLION)
TABLE 120. REST OF LAMEA LEUKAPHERESIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 121. REST OF LAMEA LEUKAPHERESIS MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 122.ADACYTE THERAPEUTICS: COMPANY SNAPSHOT
TABLE 123.ADACYTE THERAPEUTICS: OPERATING SEGMENTS
TABLE 124.ADACYTE THERAPEUTICS: PRODUCT PORTFOLIO
TABLE 125.ADACYTE THERAPEUTICS: NET SALES,
TABLE 126.ADACYTE THERAPEUTICS: KEY STRATERGIES
TABLE 127.ALLCELLS, LLC.: COMPANY SNAPSHOT
TABLE 128.ALLCELLS, LLC.: OPERATING SEGMENTS
TABLE 129.ALLCELLS, LLC.: PRODUCT PORTFOLIO
TABLE 130.ALLCELLS, LLC.: NET SALES,
TABLE 131.ALLCELLS, LLC.: KEY STRATERGIES
TABLE 132.ASAHI KASEI CORPORATION: COMPANY SNAPSHOT
TABLE 133.ASAHI KASEI CORPORATION: OPERATING SEGMENTS
TABLE 134.ASAHI KASEI CORPORATION: PRODUCT PORTFOLIO
TABLE 135.ASAHI KASEI CORPORATION: NET SALES,
TABLE 136.ASAHI KASEI CORPORATION: KEY STRATERGIES
TABLE 137.CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: COMPANY SNAPSHOT
TABLE 138.CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: OPERATING SEGMENTS
TABLE 139.CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: PRODUCT PORTFOLIO
TABLE 140.CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: NET SALES,
TABLE 141.CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: KEY STRATERGIES
TABLE 142.CERUS CORPORATION: COMPANY SNAPSHOT
TABLE 143.CERUS CORPORATION: OPERATING SEGMENTS
TABLE 144.CERUS CORPORATION: PRODUCT PORTFOLIO
TABLE 145.CERUS CORPORATION: NET SALES,
TABLE 146.CERUS CORPORATION: KEY STRATERGIES
TABLE 147.FRESENIUS KABI: COMPANY SNAPSHOT
TABLE 148.FRESENIUS KABI: OPERATING SEGMENTS
TABLE 149.FRESENIUS KABI: PRODUCT PORTFOLIO
TABLE 150.FRESENIUS KABI: NET SALES,
TABLE 151.FRESENIUS KABI: KEY STRATERGIES
TABLE 152.HAEMONETICS CORPORATION: COMPANY SNAPSHOT
TABLE 153.HAEMONETICS CORPORATION: OPERATING SEGMENTS
TABLE 154.HAEMONETICS CORPORATION: PRODUCT PORTFOLIO
TABLE 155.HAEMONETICS CORPORATION: NET SALES,
TABLE 156.HAEMONETICS CORPORATION: KEY STRATERGIES
TABLE 157.MACOPHARMA: COMPANY SNAPSHOT
TABLE 158.MACOPHARMA: OPERATING SEGMENTS
TABLE 159.MACOPHARMA: PRODUCT PORTFOLIO
TABLE 160.MACOPHARMA: NET SALES,
TABLE 161.MACOPHARMA: KEY STRATERGIES
TABLE 162.SB-KAWASUMI LABORATORIES, INC.: COMPANY SNAPSHOT
TABLE 163.SB-KAWASUMI LABORATORIES, INC.: OPERATING SEGMENTS
TABLE 164.SB-KAWASUMI LABORATORIES, INC.: PRODUCT PORTFOLIO
TABLE 165.SB-KAWASUMI LABORATORIES, INC.: NET SALES,
TABLE 166.SB-KAWASUMI LABORATORIES, INC.: KEY STRATERGIES
TABLE 167.TERUMO BCT, INC.: COMPANY SNAPSHOT
TABLE 168.TERUMO BCT, INC.: OPERATING SEGMENTS
TABLE 169.TERUMO BCT, INC.: PRODUCT PORTFOLIO
TABLE 170.TERUMO BCT, INC.: NET SALES,
TABLE 171.TERUMO BCT, INC.: KEY STRATERGIES

LIST OF FIGURES

FIGURE 1.LEUKAPHERESIS MARKET SEGMENTATION
FIGURE 2.LEUKAPHERESIS MARKET,2021-2031
FIGURE 3.LEUKAPHERESIS MARKET,2021-2031
FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
FIGURE 5.PORTER FIVE-1
FIGURE 6.PORTER FIVE-2
FIGURE 7.PORTER FIVE-3
FIGURE 8.PORTER FIVE-4
FIGURE 9.PORTER FIVE-5
FIGURE 10.TOP PLAYER POSITIONING
FIGURE 11.LEUKAPHERESIS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
FIGURE 12.LEUKAPHERESIS MARKET,BY PRODUCT,2021(%)
FIGURE 13.COMPARATIVE SHARE ANALYSIS OF DEVICES LEUKAPHERESIS MARKET,2021-2031(%)
FIGURE 14.COMPARATIVE SHARE ANALYSIS OF DISPOSABLES LEUKAPHERESIS MARKET,2021-2031(%)
FIGURE 15.LEUKAPHERESIS MARKET,BY METHOD,2021(%)
FIGURE 16.COMPARATIVE SHARE ANALYSIS OF CENTRIFUGATION LEUKAPHERESIS MARKET,2021-2031(%)
FIGURE 17.COMPARATIVE SHARE ANALYSIS OF MEMBRANE SEPARATION LEUKAPHERESIS MARKET,2021-2031(%)
FIGURE 18.COMPARATIVE SHARE ANALYSIS OF SELECTIVE ADSORPTION LEUKAPHERESIS MARKET,2021-2031(%)
FIGURE 19.LEUKAPHERESIS MARKET,BY APPLICATION,2021(%)
FIGURE 20.COMPARATIVE SHARE ANALYSIS OF THERAPEUTIC APPLICATIONS LEUKAPHERESIS MARKET,2021-2031(%)
FIGURE 21.COMPARATIVE SHARE ANALYSIS OF RESEARCH APPLICATIONS LEUKAPHERESIS MARKET,2021-2031(%)
FIGURE 22.LEUKAPHERESIS MARKET,BY END USER,2021(%)
FIGURE 23.COMPARATIVE SHARE ANALYSIS OF BLOOD CENTERS LEUKAPHERESIS MARKET,2021-2031(%)
FIGURE 24.COMPARATIVE SHARE ANALYSIS OF HOSPITALS LEUKAPHERESIS MARKET,2021-2031(%)
FIGURE 25.COMPARATIVE SHARE ANALYSIS OF OTHERS LEUKAPHERESIS MARKET,2021-2031(%)
FIGURE 26.LEUKAPHERESIS MARKET BY REGION,2021
FIGURE 27.U.S. LEUKAPHERESIS MARKET,2021-2031($MILLION)
FIGURE 28.CANADA LEUKAPHERESIS MARKET,2021-2031($MILLION)
FIGURE 29.MEXICO LEUKAPHERESIS MARKET,2021-2031($MILLION)
FIGURE 30.GERMANY LEUKAPHERESIS MARKET,2021-2031($MILLION)
FIGURE 31.FRANCE LEUKAPHERESIS MARKET,2021-2031($MILLION)
FIGURE 32.UK LEUKAPHERESIS MARKET,2021-2031($MILLION)
FIGURE 33.ITALY LEUKAPHERESIS MARKET,2021-2031($MILLION)
FIGURE 34.SPAIN LEUKAPHERESIS MARKET,2021-2031($MILLION)
FIGURE 35.REST OF EUROPE LEUKAPHERESIS MARKET,2021-2031($MILLION)
FIGURE 36.JAPAN LEUKAPHERESIS MARKET,2021-2031($MILLION)
FIGURE 37.CHINA LEUKAPHERESIS MARKET,2021-2031($MILLION)
FIGURE 38.INDIA LEUKAPHERESIS MARKET,2021-2031($MILLION)
FIGURE 39.AUSTRALIA LEUKAPHERESIS MARKET,2021-2031($MILLION)
FIGURE 40.SOUTH KOREA LEUKAPHERESIS MARKET,2021-2031($MILLION)
FIGURE 41.REST OF ASIA-PACIFIC LEUKAPHERESIS MARKET,2021-2031($MILLION)
FIGURE 42.BRAZIL LEUKAPHERESIS MARKET,2021-2031($MILLION)
FIGURE 43.SAUDI ARABIA LEUKAPHERESIS MARKET,2021-2031($MILLION)
FIGURE 44.SOUTH AFRICA LEUKAPHERESIS MARKET,2021-2031($MILLION)
FIGURE 45.REST OF LAMEA LEUKAPHERESIS MARKET,2021-2031($MILLION)
FIGURE 46. TOP WINNING STRATEGIES, BY YEAR
FIGURE 47. TOP WINNING STRATEGIES, BY DEVELOPMENT
FIGURE 48. TOP WINNING STRATEGIES, BY COMPANY
FIGURE 49.PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 50.COMPETITIVE DASHBOARD
FIGURE 51.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
FIGURE 52.ADACYTE THERAPEUTICS.: NET SALES ,($MILLION)
FIGURE 53.ALLCELLS, LLC..: NET SALES ,($MILLION)
FIGURE 54.ASAHI KASEI CORPORATION.: NET SALES ,($MILLION)
FIGURE 55.CHARLES RIVER LABORATORIES INTERNATIONAL, INC..: NET SALES ,($MILLION)
FIGURE 56.CERUS CORPORATION.: NET SALES ,($MILLION)
FIGURE 57.FRESENIUS KABI.: NET SALES ,($MILLION)
FIGURE 58.HAEMONETICS CORPORATION.: NET SALES ,($MILLION)
FIGURE 59.MACOPHARMA.: NET SALES ,($MILLION)
FIGURE 60.SB-KAWASUMI LABORATORIES, INC..: NET SALES ,($MILLION)
FIGURE 61.TERUMO BCT, INC..: NET SALES ,($MILLION)

Product Code: A09084

The global leukapheresis market was valued at $245.65 million in 2021 and is projected to reach $561.64 million by 2031 registering a CAGR of 8.6% from 2022 to 2031.

Leukapheresis is a laboratory procedure in which white blood cells are removed from a sample of blood. In this process, blood passes through a machine that takes out white blood cells and returns all other blood cells and plasma back into the bloodstream. In addition, the process includes insertion of two intravenous (IV) lines into body. One IV line removes blood while the other carries cleaned blood back to the body. This procedure takes approximately two to three hours to complete.

The growth of global leukapheresis market is majorly driven by increase in demand for leukapheresis, owing to increase in incidences and prevalence of leukemia. In addition, increase in demand for blood donations and rise in demand for leukopaks in clinical research studies responsible for the market growth. Furthermore, increase in awareness regarding leukapheresis procedures in developed countries such as the U.S. further fuel the market growth. However high cost associated with leukapheresis therapeutics and leukopak and blood transfusion safety in developing countries hinder the market growth. Conversely, increase in demand for leukapheresis in pediatric patients is anticipated to provide lucrative opportunities to the market players.

The global leukapheresis market is segmented into product, method, application, end user, and region. By product, the market is categorized into devices and disposables. On the basis of method, it is segregated into centrifugation, membrane separation, and selective adsorption. By application, it is classified into therapeutics application and research application. On the basis of end user, it is categorized into blood centers, hospitals, and others. The others segment further includes research institutes, biopharmaceutical manufacturers, and private medical settings. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Key Benefits For Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the leukapheresis market analysis from 2021 to 2031 to identify the prevailing leukapheresis market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the leukapheresis market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global leukapheresis market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Product

Devices
Disposables

By Method

Centrifugation
Membrane Separation
Selective Adsorption

By Application

Research Applications
Therapeutic Applications

By End User

Blood Centers
Hospitals
Others

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Italy
- Spain
- Rest of Europe
- Germany
- France
- UK
Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
Key Market Players
- Adacyte Therapeutics
- AllCells, LLC.
- Asahi Kasei Corporation
- Charles River Laboratories International, Inc.
- Cerus Corporation
- Fresenius Kabi
- Haemonetics Corporation
- Macopharma
- SB-Kawasumi Laboratories, Inc.
- Terumo BCT, Inc.

CHAPTER 1:INTRODUCTION

1.1.Report description
1.2.Key market segments
1.3.Key benefits to the stakeholders
1.4.Research Methodology
- 1.4.1.Secondary research
- 1.4.2.Primary research
- 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

2.1.Key findings of the study
2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

3.1.Market definition and scope
3.2.Key findings
- 3.2.1.Top investment pockets
3.3.Porter's five forces analysis
3.4.Top player positioning
3.5.Market dynamics
- 3.5.1.Drivers
- 3.5.2.Restraints
- 3.5.3.Opportunities
3.6.COVID-19 Impact Analysis on the market

CHAPTER 4: LEUKAPHERESIS MARKET, BY PRODUCT

4.1 Overview
- 4.1.1 Market size and forecast
4.2 Devices
- 4.2.1 Key market trends, growth factors and opportunities
- 4.2.2 Market size and forecast, by region
- 4.2.3 Market analysis by country
4.3 Disposables
- 4.3.1 Key market trends, growth factors and opportunities
- 4.3.2 Market size and forecast, by region
- 4.3.3 Market analysis by country

CHAPTER 5: LEUKAPHERESIS MARKET, BY METHOD

5.1 Overview
- 5.1.1 Market size and forecast
5.2 Centrifugation
- 5.2.1 Key market trends, growth factors and opportunities
- 5.2.2 Market size and forecast, by region
- 5.2.3 Market analysis by country
5.3 Membrane Separation
- 5.3.1 Key market trends, growth factors and opportunities
- 5.3.2 Market size and forecast, by region
- 5.3.3 Market analysis by country
5.4 Selective Adsorption
- 5.4.1 Key market trends, growth factors and opportunities
- 5.4.2 Market size and forecast, by region
- 5.4.3 Market analysis by country

CHAPTER 6: LEUKAPHERESIS MARKET, BY APPLICATION

6.1 Overview
- 6.1.1 Market size and forecast
6.2 Therapeutic Applications
- 6.2.1 Key market trends, growth factors and opportunities
- 6.2.2 Market size and forecast, by region
- 6.2.3 Market analysis by country
6.3 Research Applications
- 6.3.1 Key market trends, growth factors and opportunities
- 6.3.2 Market size and forecast, by region
- 6.3.3 Market analysis by country

CHAPTER 7: LEUKAPHERESIS MARKET, BY END USER

7.1 Overview
- 7.1.1 Market size and forecast
7.2 Blood Centers
- 7.2.1 Key market trends, growth factors and opportunities
- 7.2.2 Market size and forecast, by region
- 7.2.3 Market analysis by country
7.3 Hospitals
- 7.3.1 Key market trends, growth factors and opportunities
- 7.3.2 Market size and forecast, by region
- 7.3.3 Market analysis by country
7.4 Others
- 7.4.1 Key market trends, growth factors and opportunities
- 7.4.2 Market size and forecast, by region
- 7.4.3 Market analysis by country

CHAPTER 8: LEUKAPHERESIS MARKET, BY REGION

8.1 Overview
- 8.1.1 Market size and forecast
8.2 North America
- 8.2.1 Key trends and opportunities
- 8.2.2 North America Market size and forecast, by Product
- 8.2.3 North America Market size and forecast, by Method
- 8.2.4 North America Market size and forecast, by Application
- 8.2.5 North America Market size and forecast, by End User
- 8.2.6 North America Market size and forecast, by country
  - 8.2.6.1 U.S.
  - 8.2.6.1.1 Market size and forecast, by Product
  - 8.2.6.1.2 Market size and forecast, by Method
  - 8.2.6.1.3 Market size and forecast, by Application
  - 8.2.6.1.4 Market size and forecast, by End User
  - 8.2.6.2 Canada
  - 8.2.6.2.1 Market size and forecast, by Product
  - 8.2.6.2.2 Market size and forecast, by Method
  - 8.2.6.2.3 Market size and forecast, by Application
  - 8.2.6.2.4 Market size and forecast, by End User
  - 8.2.6.3 Mexico
  - 8.2.6.3.1 Market size and forecast, by Product
  - 8.2.6.3.2 Market size and forecast, by Method
  - 8.2.6.3.3 Market size and forecast, by Application
  - 8.2.6.3.4 Market size and forecast, by End User
8.3 Europe
- 8.3.1 Key trends and opportunities
- 8.3.2 Europe Market size and forecast, by Product
- 8.3.3 Europe Market size and forecast, by Method
- 8.3.4 Europe Market size and forecast, by Application
- 8.3.5 Europe Market size and forecast, by End User
- 8.3.6 Europe Market size and forecast, by country
  - 8.3.6.1 Germany
  - 8.3.6.1.1 Market size and forecast, by Product
  - 8.3.6.1.2 Market size and forecast, by Method
  - 8.3.6.1.3 Market size and forecast, by Application
  - 8.3.6.1.4 Market size and forecast, by End User
  - 8.3.6.2 France
  - 8.3.6.2.1 Market size and forecast, by Product
  - 8.3.6.2.2 Market size and forecast, by Method
  - 8.3.6.2.3 Market size and forecast, by Application
  - 8.3.6.2.4 Market size and forecast, by End User
  - 8.3.6.3 UK
  - 8.3.6.3.1 Market size and forecast, by Product
  - 8.3.6.3.2 Market size and forecast, by Method
  - 8.3.6.3.3 Market size and forecast, by Application
  - 8.3.6.3.4 Market size and forecast, by End User
  - 8.3.6.4 Italy
  - 8.3.6.4.1 Market size and forecast, by Product
  - 8.3.6.4.2 Market size and forecast, by Method
  - 8.3.6.4.3 Market size and forecast, by Application
  - 8.3.6.4.4 Market size and forecast, by End User
  - 8.3.6.5 Spain
  - 8.3.6.5.1 Market size and forecast, by Product
  - 8.3.6.5.2 Market size and forecast, by Method
  - 8.3.6.5.3 Market size and forecast, by Application
  - 8.3.6.5.4 Market size and forecast, by End User
  - 8.3.6.6 Rest of Europe
  - 8.3.6.6.1 Market size and forecast, by Product
  - 8.3.6.6.2 Market size and forecast, by Method
  - 8.3.6.6.3 Market size and forecast, by Application
  - 8.3.6.6.4 Market size and forecast, by End User
8.4 Asia-Pacific
- 8.4.1 Key trends and opportunities
- 8.4.2 Asia-Pacific Market size and forecast, by Product
- 8.4.3 Asia-Pacific Market size and forecast, by Method
- 8.4.4 Asia-Pacific Market size and forecast, by Application
- 8.4.5 Asia-Pacific Market size and forecast, by End User
- 8.4.6 Asia-Pacific Market size and forecast, by country
  - 8.4.6.1 Japan
  - 8.4.6.1.1 Market size and forecast, by Product
  - 8.4.6.1.2 Market size and forecast, by Method
  - 8.4.6.1.3 Market size and forecast, by Application
  - 8.4.6.1.4 Market size and forecast, by End User
  - 8.4.6.2 China
  - 8.4.6.2.1 Market size and forecast, by Product
  - 8.4.6.2.2 Market size and forecast, by Method
  - 8.4.6.2.3 Market size and forecast, by Application
  - 8.4.6.2.4 Market size and forecast, by End User
  - 8.4.6.3 India
  - 8.4.6.3.1 Market size and forecast, by Product
  - 8.4.6.3.2 Market size and forecast, by Method
  - 8.4.6.3.3 Market size and forecast, by Application
  - 8.4.6.3.4 Market size and forecast, by End User
  - 8.4.6.4 Australia
  - 8.4.6.4.1 Market size and forecast, by Product
  - 8.4.6.4.2 Market size and forecast, by Method
  - 8.4.6.4.3 Market size and forecast, by Application
  - 8.4.6.4.4 Market size and forecast, by End User
  - 8.4.6.5 South Korea
  - 8.4.6.5.1 Market size and forecast, by Product
  - 8.4.6.5.2 Market size and forecast, by Method
  - 8.4.6.5.3 Market size and forecast, by Application
  - 8.4.6.5.4 Market size and forecast, by End User
  - 8.4.6.6 Rest of Asia-Pacific
  - 8.4.6.6.1 Market size and forecast, by Product
  - 8.4.6.6.2 Market size and forecast, by Method
  - 8.4.6.6.3 Market size and forecast, by Application
  - 8.4.6.6.4 Market size and forecast, by End User
8.5 LAMEA
- 8.5.1 Key trends and opportunities
- 8.5.2 LAMEA Market size and forecast, by Product
- 8.5.3 LAMEA Market size and forecast, by Method
- 8.5.4 LAMEA Market size and forecast, by Application
- 8.5.5 LAMEA Market size and forecast, by End User
- 8.5.6 LAMEA Market size and forecast, by country
  - 8.5.6.1 Brazil
  - 8.5.6.1.1 Market size and forecast, by Product
  - 8.5.6.1.2 Market size and forecast, by Method
  - 8.5.6.1.3 Market size and forecast, by Application
  - 8.5.6.1.4 Market size and forecast, by End User
  - 8.5.6.2 Saudi Arabia
  - 8.5.6.2.1 Market size and forecast, by Product
  - 8.5.6.2.2 Market size and forecast, by Method
  - 8.5.6.2.3 Market size and forecast, by Application
  - 8.5.6.2.4 Market size and forecast, by End User
  - 8.5.6.3 South Africa
  - 8.5.6.3.1 Market size and forecast, by Product
  - 8.5.6.3.2 Market size and forecast, by Method
  - 8.5.6.3.3 Market size and forecast, by Application
  - 8.5.6.3.4 Market size and forecast, by End User
  - 8.5.6.4 Rest of LAMEA
  - 8.5.6.4.1 Market size and forecast, by Product
  - 8.5.6.4.2 Market size and forecast, by Method
  - 8.5.6.4.3 Market size and forecast, by Application
  - 8.5.6.4.4 Market size and forecast, by End User

CHAPTER 9: COMPANY LANDSCAPE

9.1. Introduction
9.2. Top winning strategies
9.3. Product Mapping of Top 10 Player
9.4. Competitive Dashboard
9.5. Competitive Heatmap
9.6. Key developments

CHAPTER 10: COMPANY PROFILES

10.1 Adacyte Therapeutics
- 10.1.1 Company overview
- 10.1.2 Company snapshot
- 10.1.3 Operating business segments
- 10.1.4 Product portfolio
- 10.1.5 Business performance
- 10.1.6 Key strategic moves and developments
10.2 AllCells, LLC.
- 10.2.1 Company overview
- 10.2.2 Company snapshot
- 10.2.3 Operating business segments
- 10.2.4 Product portfolio
- 10.2.5 Business performance
- 10.2.6 Key strategic moves and developments
10.3 Asahi Kasei Corporation
- 10.3.1 Company overview
- 10.3.2 Company snapshot
- 10.3.3 Operating business segments
- 10.3.4 Product portfolio
- 10.3.5 Business performance
- 10.3.6 Key strategic moves and developments
10.4 Charles River Laboratories International, Inc.
- 10.4.1 Company overview
- 10.4.2 Company snapshot
- 10.4.3 Operating business segments
- 10.4.4 Product portfolio
- 10.4.5 Business performance
- 10.4.6 Key strategic moves and developments
10.5 Cerus Corporation
- 10.5.1 Company overview
- 10.5.2 Company snapshot
- 10.5.3 Operating business segments
- 10.5.4 Product portfolio
- 10.5.5 Business performance
- 10.5.6 Key strategic moves and developments
10.6 Fresenius Kabi
- 10.6.1 Company overview
- 10.6.2 Company snapshot
- 10.6.3 Operating business segments
- 10.6.4 Product portfolio
- 10.6.5 Business performance
- 10.6.6 Key strategic moves and developments
10.7 Haemonetics Corporation
- 10.7.1 Company overview
- 10.7.2 Company snapshot
- 10.7.3 Operating business segments
- 10.7.4 Product portfolio
- 10.7.5 Business performance
- 10.7.6 Key strategic moves and developments
10.8 Macopharma
- 10.8.1 Company overview
- 10.8.2 Company snapshot
- 10.8.3 Operating business segments
- 10.8.4 Product portfolio
- 10.8.5 Business performance
- 10.8.6 Key strategic moves and developments
10.9 SB-Kawasumi Laboratories, Inc.
- 10.9.1 Company overview
- 10.9.2 Company snapshot
- 10.9.3 Operating business segments
- 10.9.4 Product portfolio
- 10.9.5 Business performance
- 10.9.6 Key strategic moves and developments
10.10 Terumo BCT, Inc.
- 10.10.1 Company overview
- 10.10.2 Company snapshot
- 10.10.3 Operating business segments
- 10.10.4 Product portfolio
- 10.10.5 Business performance
- 10.10.6 Key strategic moves and developments

白血球除去療法市場：製品別、メソッド別、用途別、エンドユーザー別：世界の機会分析および産業予測、2021-2031年

Leukapheresis Market By Product, By Method, By Application, By End User : Global Opportunity Analysis and Industry Forecast, 2021-2031

目次

第1章イントロダクション

第2章エグゼクティブサマリー

第3章市場の概要

第4章白血球除去療法市場：製品別

第5章白血球除去療法市場：メソッド別

第6章白血球除去療法市場：用途別

第7章白血球除去療法市場：エンドユーザー別

第8章白血球除去療法市場：地域別

第9章企業情勢

第10章企業プロファイル

LIST OF TABLES

LIST OF FIGURES

Key Market Segments

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

CHAPTER 2:EXECUTIVE SUMMARY

CHAPTER 3:MARKET OVERVIEW

CHAPTER 4: LEUKAPHERESIS MARKET, BY PRODUCT

CHAPTER 5: LEUKAPHERESIS MARKET, BY METHOD

CHAPTER 6: LEUKAPHERESIS MARKET, BY APPLICATION

CHAPTER 7: LEUKAPHERESIS MARKET, BY END USER

CHAPTER 8: LEUKAPHERESIS MARKET, BY REGION

CHAPTER 9: COMPANY LANDSCAPE

CHAPTER 10: COMPANY PROFILES

白血球除去療法市場：製品別、メソッド別、用途別、エンドユーザー別：世界の機会分析および産業予測、2021-2031年

Leukapheresis Market By Product, By Method, By Application, By End User : Global Opportunity Analysis and Industry Forecast, 2021-2031

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場の概要

第4章 白血球除去療法市場：製品別

第5章 白血球除去療法市場：メソッド別

第6章 白血球除去療法市場：用途別

第7章 白血球除去療法市場： エンドユーザー別

第8章 白血球除去療法市場：地域別

第9章 企業情勢

第10章 企業プロファイル

LIST OF TABLES

LIST OF FIGURES

Key Market Segments

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

CHAPTER 2:EXECUTIVE SUMMARY

CHAPTER 3:MARKET OVERVIEW

CHAPTER 4: LEUKAPHERESIS MARKET, BY PRODUCT

CHAPTER 5: LEUKAPHERESIS MARKET, BY METHOD

CHAPTER 6: LEUKAPHERESIS MARKET, BY APPLICATION

CHAPTER 7: LEUKAPHERESIS MARKET, BY END USER

CHAPTER 8: LEUKAPHERESIS MARKET, BY REGION

CHAPTER 9: COMPANY LANDSCAPE

CHAPTER 10: COMPANY PROFILES

第1章イントロダクション

第2章エグゼクティブサマリー

第3章市場の概要

第4章白血球除去療法市場：製品別

第5章白血球除去療法市場：メソッド別

第6章白血球除去療法市場：用途別

第7章白血球除去療法市場：エンドユーザー別

第8章白血球除去療法市場：地域別

第9章企業情勢

第10章企業プロファイル